These data indicated that the addition of a vaccine consisting of Ad-vector plus N-803 adjuvant to bintrafusp alfa plus SX-682 therapy has the potential to increase the proliferation and cytotoxic functionality of tumor-infiltrating CD8+ T cells, while promoting a more diversified TCR repertoire in the tumor (Figure 6). Here, CD8A is linked to neoplasm.